THE ROLE OF MYONECTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.

Background: Diabetes is a chronic devastating disease characterized by remarkable tissue damage.

Aim: This prospective study conducted in Tikrit City aimed to investigate the role of myonectin and glycemic control parameters in type 2 diabetes (T2DM).

Methods: The study enrolled 60 patients with T2DM and 30 controls participants. Blood withdrawn, serum separated, serum myonectin and glycemic control parameters were quantified using Cobas C 111 analyzer. The mean serum level FBS (263.60±130.83) and HbA1C (97.56±15.54%) in T2DM patients compared with the control group (p≤0.0001). Myonectin level (pg/ml) significantly reduced (p>0.005) in T2DM (292.78±110.32) compared with the control group (379.72±140.64).

Conclusions: Circulating myonectin levels were decreased in T2DM patients. Moreover, serum myonectin levels were correlated with metabolic markers of T2DM. These data suggest that myonectin may be a useful marker in predicting the development of T2DM.